Is osteoarthritis an infection-associated disease and a target for chemotherapy?

Chemotherapy

Volumn 53, Issue 1, 2007, Pages 1-9

  Rozin, Alexander ^a,b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cotrimoxazole; Osteoarthritis; Recurrent urinary tract infection

Indexed keywords

AZATHIOPRINE; BCG VACCINE; CORTICOSTEROID; COTRIMOXAZOLE; CYTOKINE; DERMATAN SULFATE; DIACETYLRHEIN; DOXYCYCLINE; GLUCOSAMINE; HYALURONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; SOMATOMEDIN; SULFONAMIDE; TOLL LIKE RECEPTOR; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CARTILAGE DEGENERATION; CHEMOPROPHYLAXIS; CHEMOTHERAPY; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FECES MICROFLORA; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; INNATE IMMUNITY; JOINT; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PRURITUS; RECURRENT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SPINE DISEASE; TREATMENT RESPONSE; URINARY TRACT INFECTION; VEGETARIAN DIET; WEGENER GRANULOMATOSIS;

ADULT; AGED; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BACTERIA; CARTILAGE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; MIDDLE AGED; OSTEOARTHRITIS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 33846420191     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098243     Document Type: Review

References (64)

1. Brooks PM: Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumatol 2002;14:573-577.
2. Goldring MB: Anticytokine therapy for osteoarthritis. Expert Opin Biol Ther 2001;1:817-829.
3. Yasuda T, Poole AR: A fibronectin fragment induces type II collagen degradation by collagenase through an interleukin-1-mediated pathway. Arthritis Rheum 2002;46:138-148.
4. Aigner T, Kuzz B, Fukui N, Sandell L: Roles of chondrocytes in the pathogenesis of osteoarthritis. Curr Opin Rheumatol 2002;14:578-584.
5. Attur MG, Dave M, Akamatsu M, Katoh M, Amin AR: Osteoarthritis or osteoarthrosis: the definition of inflammation becomes a semantic issue in the genomic era of molecular medicine. Osteoarthritis Cartilage 2002;10:1-4.
6. Roshak AK, Callahan JF, Blake SM: Small-molecule inhibitors of NF-kappaB for the treatment of inflammatory joint disease. Curr Opin Pharmacol 2002;2:316-321.
7. Rozin A, Schapira D, Braun-Moscovici Y, Nahir AM: Cotrimoxazole treatment for rheumatoid arthritis. Semin Arthritis Rheum 2001;31:133-141.
8. Gradon JD, Zimbalist EH: Is trimethoprim-sulfamethoxazole helpful in Crohn's disease? J Clin Gastroenterol 1990;12:598-599.
9. Savidge RS: Trimethoprim and sulfamethoxazole in ulcerative colitis. Postgrad Med J 1969;45(suppl):101-103.
10. Gembitskii EV, Glazunov AV, Zhiliaev EBV, Prekhorova EG: Etiology and treatment of temporal arteritis. Klin Med (Mosk) 1994;72:18-21.
11. Rozin AP, Militianu D, Edoute Y: OARSI response criteria in assessment of co-trimoxazole influence on refractory knee osteoarthritis during prophylaxis of recurrent UTI. EULAR-Berlin 2004. Ann Rheum Dis 2004;63(suppl 1):358.
12. Dougados M, LeClaire P, van der Heijde D, Bloch DA, Bellamy N, Altman RD: A report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative. Osteoarthritis Cartilage 2000;8:395-403.
13. Pelletier JP, Martel-Pelletier J, Abramson SB: Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic agents. Arthritis Rheum 2001;44:1237-1247.
14. Spector TD, Hart DJ, Nandra D, Doyle DV, Mackillop N, Gallimore JR, Pepys MB: Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997;40:723-727.
15. Sharif M, Shepstone L, Elson CJ, Dieppe PA, Kirwan JR: Increased serum C reactive protein may reflect events that precede radiographic progression in osteoarthritis of the knee. Ann Rheum Dis 2000;59:71-74.
16. Saxne T, Lindell M, Mansson B, Petersson IF, Heinegard D: Inflammation is a feature of the disease process in early knee joint osteoarthritis. Rheumatology 2003;42:903-904.
17. Pelletier JP, McCollum R, Cloutier JM, Martell-Pelletier J: Synthesis of metalloproteases and interleukin-6 (IL-6) in human osteoarthritic synovial membrane is an IL-1 mediated process. J Rheumatol 1995;22:109-114.
18. Goldring MB: The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res 1999;40:1-11.
19. Malemud CJ, Islam N, Haqqi TM: Pathophysiological mechanisms in osteoarthritis lead to novel therapeutic strategies. Cells Tissues Organs 2003;174:34-48.
20. Alaaeddine N, Di Battista JA, Pelletier JP, Cloutier JM, Kiansa K, Dupuis M, Martell-Pelletier J: Osteoarthritis synovial fibroblasts possess an increased level of tumor necrosis factor-receptor 55 (TNF R55) that mediates biological activation of TNF-alpha. J Rheumatol 1997;24:1985-1994.
21. Webb GR, Westacott CI, Elson CJ: Cartilage tumor necrosis factor alpha receptors and focal loss of cartilage in osteoarthritis. Osteoarthritis Cartilage 1997;5:427-437.
22. Webb GR, Westacott CI, Elson CJ: Osteoarthritis synovial fluid and synovium supernatants up-regulate tumor necrosis factor receptors on human articular chondrocytes. Osteoarthritis Cartilage 1998;6:167-176.
23. Shibakava A, Aoki H, Masuko-Hongo K, Kato T, Tanaka M, Nishioka K, Nakamura H: Presence of pannus-like tissue on osteoarthritis cartilage and its histological character. Osteoarthritis Cartilage 2003;11:133-140.
24. Raynauld JP, Buckland-Wright C, Ward R, Choquette D, Haraoui B, Martel-Pelletier J, Uthman I, Khy V, Tremblay JL, Bertrand C, Pelletier JP: Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003;48:370-377.
25. Ghilchik MW, Morris AS, Reeves DS: Immunosuppressive powers of the antibacterial agent trimethoprim. Nature 1970;227:393-394.
26. DeRemee RA, McDonald TJ, Weiland LH: Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc 1985;60:27-32.
27. Yuasa K, Tokitsu M, Goto H, Kato H, Shimada K: Wegener's granulomatosis: diagnosis by transbronchial lung biopsy, evaluation by gallium scintigraphy and treatment with sulfamethoxazole/trimethoprim. Am J Med 1988;84:371-372.
28. Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CGM, Dutch Co-Trimoxazole Wegener Study Group: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 1996;335:16-20.
29. Brouwer E, Huitema MG, Mulder AH, Heeringa P, van Goor H, Tervaert JW, Weening JJ, Kallenberg CG: Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. Kidney Int 1994;45:1120-1131.
30. Durupinar B: The effect of drugs on the immune response. Mikrobiyol Bul 1987;21:117-130.
31. Gaylarde PM, Sarkany I: Suppression of thymidine uptake of human lymphocytes by cotrimoxazole. Br Med J 1972;3:144-146.
32. Stirling A, Worthington T, Rafiq M, Lambert PA, Elliott TS: Association between sciatica and Propionibacterium acnes. Lancet 2001;357:2024-2025.
33. Tan HH: Antibacterial therapy for acne: a guide to selection and use of systemic agents. Am J Clin Dermatol 2003;4:307-314.
34. Rozin AP, Schapira D, Bergman R: Alopecia areata and relapsing polychondritis or mosaic autoimmunity? The first experience of co-trimoxazole treatment. Ann Rheum Dis 2003;62:778-780.
35. Rozin A: Is Behcet's syndrome associated with infection? Ann Rheum Dis 2005;64:513-514.
36. Rozin AP, Nahir AM: Is SAPHO syndrome a target for antibiotic therapy? Clin Rheumatol, in press.
37. Israel HL: Sulfamethoxazole-trimethoprim therapy for Wegener's granulomatosis. Arch Intern Med 1988;148:2293-2295.
38. Kahn CR, Shechter Y: Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas; in Gilman AG, Rall TW, Nies AS, Taylor P (eds): Goodman and Gilmann's The Pharmacological Basis of Therapeutics, ed 8. Singapore, McGraw-Hill, 1991, vol 2, pp 1463-1495.
39. Rutschmann OT, Wicki J, Micheli P, Kondo Oestreicher M, Guillermin Spahr ML, Droz M: Co-trimoxazole administration: a rare cause of hypoglycemia in elderly persons. Schweiz Med Wochenschr 1998;128:1171-1174.
40. Aigner T, Kurz B, Fukui N, Sandell L: Roles of chondrocytes in the pathogenesis of osteoarthritis. Curr Opin Rheumatol 2002;14:578-584.
41. Inoue T, Saito H, Fukushima R, Inaba T, Lin MT, Fukatsu K, et al: Growth hormone and insulin-like growth factor I enhance host defense in a murine sepsis model. Arch Surg 1995;130:1115-1122.
42. Hui W, Rowan AD, Cawston T: Modulation of the expression of matrix metalloproteinase and tissue inhibitors of metalloproteinases by TGF-beta1 and IGF-1 in primary human articular and bovine nasal chondrocytes stimulated with TNF-alpha. Cytokine 2001;16:31-35.
43. Loesser RF, Shanker G: Autocrine stimulation by insulin-like growth factor 1 and insulin-like growth factor 2 mediate chondrocyte survival in vitro. Arthritis Rheum 2000;43:1552-1559.
44. Hsu SC, Gavrilin MA, Kee HH, Wu CC, Han SH, Lai MZ: NF-kappaB dependent Fas ligand expression. Eur J Immunol 1998;29:2948-2956.
45. Matsui K, Fine A, Zhu B, Marshak-Rothstein A, Ju ST: Identification of two NF-kappaB sites in CD95 ligand (Fas ligand) promoter: functional analysis in T cell hybridoma. J Immunol 1998;161:3469-3473.
46. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by directed inhibition of IkappaB kinases alpha and beta. Gastroenterology 2000;119:1209-1218.
47. Peltonen R, Kjeldsen-Kragh J, Haugen M, et al: Changes of faecal flora in rheumatoid arthritis during fasting and one-year vegetarian diet. Br J Rheumatol 1994;33:638-643.
48. Peltonen R, Nenonen M, Helve T, Hanninen O, Toivanen P, Eerola E: Faecal microbial flora and disease activity in rheumatoid arthritis during a vegan diet. Br J Rheumatol 1997;36:64-68.
49. Toivanen P, Eerola E: A vegan diet changes the intestinal flora. Rheumatology 2002;41:950-951.
50. Klinman D: Does activation of the innate immune system contribute to the development of rheumatoid arthritis. Arthritis Rheum 2003;48:590-593.
51. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-396.
52. Medzhitov R, Janeway CA Jr: Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997;9:4-9.
53. Medzhitov R, Janeway CA Jr: Innate immunity: the virtues of a nonclonal system of recognition. Cell 1998;91:295-298.
54. Klinman DM, Yi A, Beaucage SL, Conover J, Krieg AM: CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and INF gamma. Proc Natl Acad Sci USA 1996;93:2879-2883.
55. Krieg AM, Yi A, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al: CpG motifs in bacterial NA trigger direct B-cell activation. Nature 1995;374:546-548.
56. Kyburz D, Rethage J, Seibl R, Lauener R, Gay RE, Carson DA, Gay S: Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. Arthritis Rheum 2003;48:642-650.
57. Tolusso B, Fabris M, Di Poi E, Assaloni R, Tomietto P, Ferracciolli GF: Response of mononuclear cells to lipopolysaccharide and CpG oligonucleotide stimulation: possible additive effect in rheumatoid inflammation. Ann Rheum Dis 2003;62:284-285.
58. Van der Heijden I, Wilbrink B, Tchetverikov I, Schrijver IA, Schouls LM, Hazenberg MP, et al: Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum 2000;43:593-598.
59. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A: Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-607.
60. Thornsberry C, Sahm DF: Antimicrobial resistance in respiratory tract pathogens: results of an international surveillance study. Chemotherapy 2000;46:14-23.
61. Zhanel GG, Karlowsky JA, Schwartz B, Jensen SB, Hoban DJ: Mecillinam activity compared to ampicillin, trimethoprin/sulfamethoxazole, ciprofloxacin and nitrofurantoin against urinary tract isolates of gram-negative bacilli. Chemotherapy 1998;44:391-396.
62. Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, Wolfe F, Schnitzer TJ, Moreland LW, Manzi S, Bradley JD, Sharma L, Oddis CV, Hugenberg ST, Heck LW: Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 2005;52:2015-2025.
63. Biggee BA, Blinn CM, McAlindon TE, Nuite M, Silbert JE: Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheum Dis, in press.
64. Barthe L, Woodley J, Lavit M, Przybylski C, Phillibert C, Houin G: In vitro intestinal degradation and absorption of chondroitin sulfate, a glycosaminoglycan drug. Arzneimittelforschung 2004;54:286-292.